
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Mercks Keytruda in phase three trial.
Music
Trailers
DailyVideos
India
Pakistan
Afghanistan
Bangladesh
Srilanka
Nepal
Thailand
StockMarket
Business
Technology
Startup
Trending Videos
Coupons
Football
Search
Download App in Playstore
Download App
Best Collections
2-Abuse  3-Airstrike  2-Blasts  6-Bomb  3-Disaster  2-Earthquake  1-Kidnap  34-Killed  1-Rape  6-Terror  95-War  
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Mercks Keytruda in phase three trial.